A(H1N1)pdm09 vaccination of health care workers: Improved immune responses in low responders following revaccination

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1660-1669

  Pathirana, Rishi Delan ^a   Bredholt, Geir ^a   Akselsen, Per Espen ^b   Pedersen, Gabriel Kristian ^a   Cox, Rebecca Jane ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VACCINE;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MALE; MEMORY CELL; NORWAY; PRIORITY JOURNAL; REVACCINATION; SINGLE DRUG DOSE; TH1 CELL;

ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; GENE EXPRESSION REGULATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84869003643     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis589     Document Type: Article

References (37)

1. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52.
2. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
3. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
4. Ikematsu H, Nagai H, Kawashima M, et al. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888-93.
5. Madhun AS, Akselsen PE, Sjursen H, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266-73.
6. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)- Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77.
7. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46.
8. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66.
9. WHO. H1N1 in post-pandemic period. http://www.who.int/media centre/news/statements/2010/h1n1-vpc-20100810/en/index.html. Accessed 18 September 2012.
10. CDC. Vaccine Selection for the 2011-2012 Influenza Season. http://www.cdc.gov/flu/about/qa/vaccine-selection.htm. Accessed 18 September 2011.
11. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 2005; 23:2251-5.
12. Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER. C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97.
13. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995; 171:198-203.
14. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994; 12:993-9.
15. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigenspecific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22.
16. Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol 2011; 74:210-8.
17. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79:167-74.
18. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012; 205:610-20.
19. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71.
20. Dormitzer PR, Galli G, Castellino F, et al. Influenza vaccine immunology. Immunol Rev 2011; 239:167-77.
21. Li GM, Chiu C, Wrammert J, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 2012; 109:9047-52.
22. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12:786-95.
23. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81:215-28.
24. Bende RJ, van Maldegem F, Triesscheijn M, Wormhoudt TA, Guijt R, van Noesel CJ. Germinal centers in human lymph nodes contain reactivated memory B cells. J Exp Med 2007; 204:2655-65.
25. Berkowska MA, Driessen GJ, Bikos V, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011; 118:2150-8.
26. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med 2011; 208:2599-606.
27. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93.
28. Onodera T, Takahashi Y, Yokoi Y, et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc Natl Acad Sci USA 2012; 109:2485-90.
29. Baer J, Santiago F, Yang H, et al. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 2010; 28:907-15.
30. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 2010; 84:9217-26.
31. Jelley-Gibbs DM, Strutt TM, McKinstry KK, Swain SL. Influencing the fates of CD4 T cells on the path to memory: lessons from influenza. Immunol Cell Biol 2008; 86:343-52.
32. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 2002; 76:12388-93.
33. Strutt TM, McKinstry KK, Dibble JP, et al. Memory CD4+ T cells induce innate responses independently of pathogen. Nat Med 2010; 16:558-64, 1p following 64
34. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses 2011; 5:426-37.
35. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81:8468-76.
36. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106:3877-82.
37. Pedersen G, Madhun AS, Breakwell L, et al. Th1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66.